Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

iRhythm Technologies, Inc. - Common Stock (NQ: IRTC )

110.16 +3.59 (+3.37%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 538,953
Open 104.71
Bid (Size) 110.14 (1)
Ask (Size) 110.25 (3)
Prev. Close 106.57
Today's Range 104.71 - 110.32
52wk Range 55.92 - 128.52
Shares Outstanding 29,403,360
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Reflecting On Patient Monitoring Stocks’ Q4 Earnings: DexCom (NASDAQ:DXCM)
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how patient monitoring stocks fared in Q4, starting with DexCom... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Breaking Down iRhythm Technologies: 6 Analysts Share Their Views
Via Benzinga

Performance

YTD
+23.17%
+23.17%
1 Month
-0.16%
-0.16%
3 Month
+26.67%
+26.67%
6 Month
+55.42%
+55.42%
1 Year
-7.16%
-7.16%

More News

Read More
iRhythm (NASDAQ:IRTC) Reports Strong Q4, Stock Soars
Via StockStory
iRhythm Technologies Announces Fourth Quarter and Full Year 2024 Financial Results
From iRhythm
Via GlobeNewswire
Earnings Scheduled For February 20, 2025
Via Benzinga
Critical Insights From iRhythm Technologies Analyst Ratings: What You Need To Know
Via Benzinga
Forecasting The Future: 6 Analyst Projections For iRhythm Technologies
Via Benzinga
Earnings Preview For iRhythm Technologies
Via Benzinga
iRhythm (IRTC) To Report Earnings Tomorrow: Here Is What To Expect
Via StockStory
iRhythm Technologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
From iRhythm
Via GlobeNewswire
iRhythm Technologies Shares Preliminary Fourth Quarter 2024 Highlights and Business Update at the 43rd Annual J.P. Morgan Healthcare Conference
From iRhythm
Via GlobeNewswire
iRhythm Technologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From iRhythm
Via GlobeNewswire
Top 3 Robotics and Automation Stocks for the Next AI Boom
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
Via Benzinga
iRhythm Technologies to Participate in the Citi 2024 Global Healthcare Conference
From iRhythm
Via GlobeNewswire
iRhythm Data Presented at the American Heart Association 2024 Scientific Sessions Reinforce Clinical and Health Economic Value of Zio Long-Term Continuous Monitoring
From iRhythm
Via GlobeNewswire
iRhythm Technologies to Participate in the Wolfe Research 2024 Healthcare Conference
From iRhythm
Via GlobeNewswire
IRHYTHM ALERT: Bragar Eagel & Squire, P.C. is Investigating iRhythm Technologies, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
iRhythm Technologies Receives FDA 510(k) Clearance for Design Modifications to Its Zio® AT Device
From iRhythm
Via GlobeNewswire
iRhythm Technologies Announces Third Quarter 2024 Financial Results
From iRhythm
Via GlobeNewswire
Newly Published Research Shows 14-Day Monitoring Detected Almost Three Times More Nonsustained Ventricular Tachycardia Than Standard 48-Hour Monitoring in Patients with Hypertrophic Cardiomyopathy
From iRhythm
Via GlobeNewswire
Trump Media & Tech, ImmunityBio, And iRhythm Are Among Top 10 Mid Cap Gainers Last Week (Oct 21-Oct 25): Are The Others In Your Portfolio?
Via Benzinga
Topics Government
Exposures Political
IRHYTHM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of iRhythm Technologies, Inc. - IRTC
From Kahn Swick & Foti, LLC
Via Business Wire
Nasdaq Turns Higher; Verizon Shares Fall After Q3 Results
Via Benzinga
With FDA Approval iRhythm May Be Able To Lift Regulatory Overhang, Investor Skepticism, Analyst Says
Via Benzinga
Exposures Product Safety
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.